The Lead Episode 156: A Discussion of The Association Between Atrial Fibrillation Burden and Quality of Life: A Substudy of the SHAM-PVI Trial
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
In this episode of The Lead, host Christopher Kowalewski, MD, is joined by John M. Mandrola, MD, and Nassir F. Marrouche, MD, FHRS, to discuss the journal article, The Association Between Atrial Fibrillation Burden and Quality of Life: A Substudy of the SHAM-PVI Trial. Together, they explore the relationship between atrial fibrillation burden and quality of life, reviewing findings from this substudy of the SHAM-PVI Trial and discussing their relevance to patient-centered outcomes.
Learning Objectives
- Review the key findings from the SHAM-PVI Trial substudy examining the association between atrial fibrillation burden and quality of life.
- Discuss the relationship between atrial fibrillation burden and patient-reported quality-of-life outcomes.
- Explore the implications of assessing both arrhythmia burden and quality of life when evaluating treatment outcomes in atrial fibrillation.
Host: Christopher Kowalewski, MD
Guests: John M. Mandrola, MD and Nassir F. Marrouche, MD, FHRS
Disclosures:
Christopher Kowalewski, MD
No relevant disclosures
John M. Mandrola, MD
No relevant disclosures
Nassir F. Marrouche, MD, FHRS
• Honoraria/Speaking/Consulting Fee/Speaker's Bureau: Biosense Webster, Inc., Boston Scientific, AtriCure, Inc., Abbott, Sanofi
• Research: Abbott, Biosense Webster, Inc., Medtronic, Siemens, General Electric, Boston Scientific, Sanofi, Samsung